Letrozole
11 NDCs across 7 manufacturers|10 Generic,1 Brand
Letrozole is used to treat breast neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 25, 1997, and the first generic was approved Dec 24, 2008. FDA's Orange Book lists 7 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $21 million on Letrozole across 862,000 claims for 214,000 beneficiaries.
Letrozole is available as 11 NDCs from 7 manufacturers (10 generic, 1 brand), with NADAC prices from $0.14 to $27.12 per EA — the most expensive product costs about 187× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
11
10G / 1B
Manufacturers
7
competing in market
Price Spread
$0.14 – $27.12
per EA
7d Activity
avg -4.1% WoW · of 11 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Breckenridge Pharmaceutical Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Aromatase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
7 manufacturers producing LETROZOLE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
FEMARA 2.5 MG TABLET | $27.1160 per EA | — |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
LETROZOLE 2.5 MG TABLET | $0.1450 per EA | -4.06% |
Frequently Asked Questions
What is Letrozole used to treat?
Letrozole is used to treat breast neoplasms, per the National Library of Medicine's MED-RT classification.
When did Letrozole become available as a generic?
FDA approved the first generic Letrozole (ANDA) on Dec 24, 2008. The Orange Book currently lists 7 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Letrozole?
In 2024, Medicare Part D spent $21 million on Letrozole across 862,000 claims for 214,000 beneficiaries.
How many Letrozole products are on the market?
The Letrozole drug market contains 11 NDCs from 7 manufacturers — 10 generic and 1 brand product.
What is the price range for Letrozole?
NADAC reference prices for Letrozole range from $0.1450 to $27.1160 per EA — the most expensive product costs about 187× the cheapest.
Is generic Letrozole cheaper than brand?
The average generic NADAC for Letrozole is $0.1450 per EA, versus $27.1160 for brand-labeled products — brand versions average about 187× the generic price.
Which manufacturers make Letrozole?
7 manufacturers list Letrozole in NADAC. Ranked by number of NDCs, the largest are Breckenridge Pharmaceutical Inc. (3), Accord Healthcare Inc. (2), Chartwell RX LLC (2), Novartis Pharmaceuticals Corporation (1), AvPAK (1).
How has the price of Letrozole changed recently?
Over the past 7 days, 0 Letrozole NDCs rose and 10 fell, with a market-wide average change of -4.1%.